Quotient Biodiagnostics, Inc. Sustainability Profile
Quotient Biodiagnostics, Inc., a leading player in the biotechnology sector, is headquartered in the United States. Founded in 2012, the company has rapidly established itself in the field of blood diagnostics, focusing on innovative solutions for transfusion medicine. With a commitment to enhancing patient safety, Quotient offers unique products such as the MosaiQ™ platform, which streamlines blood grouping and antibody screening processes. The company operates primarily in North America and Europe, positioning itself as a key provider of advanced diagnostic technologies. Notable achievements include regulatory approvals that have bolstered its market presence. Quotient Biodiagnostics continues to set itself apart through its dedication to quality and innovation, making significant strides in the evolving landscape of medical diagnostics.
DitchCarbon Score
How does Quotient Biodiagnostics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Quotient Biodiagnostics, Inc.'s score of 18 is lower than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Quotient Biodiagnostics, Inc.'s reported carbon emissions
Quotient Biodiagnostics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Quotient Biodiagnostics may inherit climate commitments or emissions data from its parent organisation; however, no specific details have been provided regarding such cascaded information. The company appears to be in the early stages of establishing its climate strategy and emissions reporting framework. In the context of the industry, it is essential for companies like Quotient Biodiagnostics to develop robust climate commitments and reduction initiatives to align with global sustainability goals and respond to increasing regulatory and consumer expectations regarding environmental responsibility.
How Carbon Intensive is Quotient Biodiagnostics, Inc.'s Industry?
How Carbon Intensive is Quotient Biodiagnostics, Inc.'s Location?
Quotient Biodiagnostics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Quotient Biodiagnostics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
